Vanda Pharmaceuticals Inc. (VNDA) Balance Sheet

The steady compression of equity suggests the balance sheet is weakening rather than strengthening over the ten-quarter window. Total assets have declined in parallel, indicating the shrinkage is being funded by cash consumption and asset drawdown rather than new capital. Investors should monitor whether the rate of equity erosion moderates as operating losses narrow, since the current trajectory points toward a thinner cushion against future shocks.

The fall in the current ratio reflects a shrinking pool of current assets relative to obligations, even though the absolute level still exceeds 1.0. Cash of $61.9M appears modest relative to the scale of recent quarterly operating losses, which the income statement analysis places in the tens of millions per quarter. This suggests the liquidity buffer may be finite and warrants close attention to the timing of future cash needs.

Leverage is currently light, so near-term refinancing pressure appears limited based on the reported figures. The reappearance of $22.0M of debt after a zero reading in 2026Q2 is worth investigating, since its purpose and terms are not visible in the supplied data. Lower leverage limits fixed obligations, but it also means the balance sheet depends heavily on equity and cash rather than on a debt-supported operating base.

The rising goodwill share suggests the asset base is becoming more concentrated in acquisition-related intangibles while tangible assets shrink. Net PP&E of $23.2M is small relative to total assets, consistent with an asset-light model. Because goodwill is a large fraction of the remaining equity base, any future impairment would likely have a disproportionate effect on book value, which investors should keep in view.